|
Market Cap (19-May) $1,588,165,888 (454th) |
Close (30-Jun) $12.25 |
Volume (30-Jun) 261,029 |
Shortsold (5-May) 7,255,072 (5.76%) (39th) |
|
52w High $24.00 |
52w Low $8.61 |
P/E 77.52 |
EPS 1.09 |
NEU released this announcement to the ASX on 3 September 2021, 11:41. The announcement is marked as price sensitive, and is 2 page(s) in length and 152.03kb in size.
You can view all announcements from NEU and see how they appear on a price chart on the announcements page.
At the date of this announcement, NEU was 0.144% short sold according to ASIC data. It was ranked the 405th most shorted stock on the ASX. It is now ranked as the 39th most shorted stock on the ASX with 5.756% of total shares short sold as of the latest reported data (05 May 2025).
| Other Recent Announcements from NEU | |
|---|---|
| Neuren completes enrolment in Phelan-McDermid Phase 2 trial | 30 June 2023, 9:36 |
| Neuren opens first site in US for Prader-Willi Phase 2 trial | 28 June 2023, 9:55 |
| Change of Director's Interest Notice | 14 June 2023, 18:44 |
| FDA grants Orphan Drug designation for Prader-Willi syndrome | 3 September 2021, 11:41 |
| Angelman IND and Ethics applications submitted for NNZ-2591 | 1 September 2021, 9:29 |
| Trofinetide Rett syndrome clinical trial in girls aged 2-5 | 1 September 2021, 9:10 |
| R&D Tax Incentive Advance Overseas Finding Approval | 30 August 2021, 9:42 |
You must be logged in to post a reply.
Neuren Pharmaceuticals 